Chronic graft-versus-host disease (GVHD) refractory to standard immunosuppressive therapy remains a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Thalidomide may be effective in some patients with high-risk or refractory chronic GVHD. We report a single-institution study of thalidomide in 37 BMT patients with extensive chronic GVHD refractory to standard immunosuppressive therapy. Acute GVHD occurred in 34 (91%) of patients and evolved progressively into chronic GVHD in 23 (62%) patients. Thalidomide was added to standard immunosuppressive therapy a median of 11 months (range 0-105 months) after the diagnosis of chronic GVHD. Fourteen of 37 (38%) patients responded after introduction of thalidomide (one complete, 13 partial). Ten of 21 (46%) children and four of 16 (25%) adults responded. Responses were seen in eight of 17 (47%) recipients of related donor marrow and six of 20 (30%) recipients of unrelated donor marrow. Eight of 23 (34%) patients with progressive onset of chronic GVHD showed a response. There were no deaths among the responders. The remaining 23 patients (62%) did not respond and of these only two survive, one with progressive scleroderma, and the other with bronchiolitis obliterans. Chronic GVHD with associated infection (most commonly disseminated fungal infection) was a major contributor to mortality in all cases. Overall, after initiation of thalidomide, the 2-year Kaplan-Meier survival was 41% (95% C.I. 24%-59%). We conclude that thalidomide is a useful and well-tolerated therapy for patients with previously treated refractory chronic GVHD, including those with progressive onset of chronic GVHD, recipients of unrelated donor marrow, and children. Earlier introduction of thalidomide as an adjunct to standard immunosuppressive therapy may lead to more frequent responses and possible better survival. Bone Marrow Transplantation (2000) 26, 865-869.
Chronic graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT), occurring with a frequency of 30% to 50% after related donor BMT. 1 Progressive onset from acute GVHD, lichenoid mucosal changes, and high serum bilirubin have all been reported previously to predict poor outcome, with an actuarial survival of only 20% for patients with two or more of these risk factors.
2 Thrombocytopenia is also known to be an important adverse prognostic factor. 3 Most patients who fail to respond to immunosuppressive regimens containing prednisone and cyclosporine and/or azathioprine ultimately die from their chronic GVHD, with infection as a frequent terminal event. 4 Thalidomide was first shown to modify GVHD in a series of animal experiments conducted almost 30 years ago. 5 Early reports of patient experience with thalidomide suggested benefit in both acute and chronic GVHD after BMT. 6, 7 Vogelsang et al 8 demonstrated the efficacy of thalidomide in a rat model of GVHD, providing a rationale for their subsequent study of thalidomide in 44 patients with refractory or high-risk chronic GVHD. 9 This preliminary trial indicated that thalidomide was safe and effective in chronic GVHD. At the time of this study, several other institutions including ours initiated similar trials of thalidomide, some of which have been described recently. 10, 11 We now report the University of Minnesota experience with thalidomide in related and unrelated transplant recipients with chronic GVHD refractory to intensive first-line immunosuppressive therapy.
Materials and methods
Thirty-seven patients received thalidomide for refractory chronic GVHD following allogeneic BMT at the University of Minnesota. Preparative regimens, protocols for supportive care, and GVHD prophylaxis in this patient group have been described previously. 12, 13 Most patients received cyclosporine and methotrexate as GVHD prophylaxis. No patient received T lymphocyte-depleted bone marrow.
Data regarding GVHD diagnosis, therapy, clinical course, and response to therapy were collected prospectively by the University of Minnesota Bone Marrow Transplant Biostatistics Facility and Database. Where necessary, additional information was obtained by review of individual patient records. Chronic GVHD was recognized clinically and the diagnosis confirmed histologically in all cases.
Bone Marrow Transplantation
All patients treated with thalidomide had extensive chronic GVHD, as defined by standard criteria. 14, 15 The mode of onset of chronic GVHD was classified as de novo if there was no prior acute GVHD, quiescent if prior acute GVHD had previously completely resolved, and progressive if acute GVHD had not completely resolved.
Patients were deemed to have refractory chronic GVHD, and thus, to be eligible for thalidomide, if they had failed to improve, or showed evidence of progressive disease, after at least one course of standard immunosuppressive therapy including corticosteroids and cyclosporine. Thalidomide was administered orally, starting at 50 mg four times daily. As tolerated, at 2-4-week intervals, the dose was increased, in 200 mg/day increments to a target dose in adults of at least 800 mg daily and in children of 12 mg/kg daily. Drug levels were not obtained. Informed consent was obtained in all cases, and the study was carried out in accordance with the guidelines of the University of Minnesota Institutional Review Board committee on the use of human subjects in research, and with the approval of the United States Food and Drug Administration.
Patients receiving thalidomide therapy for chronic GVHD were scheduled for review at least every 3 months. Prior immunosuppressive regimens were continued during the initiation of thalidomide. Complete response was defined as no evidence of GVHD affecting any organ or system. Partial response was defined as improvement in one or more involved organs, without evidence of progression in any involved organ. No response was defined as no improvement in one or more involved organs, or progression of chronic GVHD on therapy. Patients whose best response was transient (not maintained for at least 6 months or to last contact) or those who died within 3 months of commencing thalidomide were considered non-responders. Prior immunosuppressive regimens were continued at least during the initiation of thalidomide.
Patient survival was determined using the Kaplan-Meier product limit method with 95% confidence intervals derived from standard errors. Patients were censored at the time of death, second transplant, or date of last contact. In comparisons of survival between subgroups, P-values were determined using log-rank tests. Cox regression was used to assess the independent association of prognostic factors with survival. Factors included in the regression analysis were age, donor type, gender, type of chronic GVHD, time to initiation of thalidomide, HLA disparity, and time to chronic GVHD.
Results
The clinical characteristics of the thirty-seven patients entered in this study are shown in Table 1 . All patients had extensive chronic GVHD, with involvement of at least two organs in most (81%). Progressive onset of disease from pre-existing acute GVHD occurred in 23 (62%) patients. Median time to onset of chronic GVHD after BMT was 4 months (range 2-17 months). All patients received standard immunosuppressive therapy for chronic GVHD, as indicated in Table 1 . The median duration of this therapy before starting thalidomide was 11 months, with a range from 0 to 105 months. At the time of starting thalidomide, all but two patients had progressive or non-responsive chronic GVHD in the setting of combination immunosuppressive therapy, rather than a simple flare during tapering of this therapy. Two patients who were receiving only prednisone therapy had previously responded to standard immunosuppressive therapy, but had progressive disease when thalidomide was introduced. In addition, two patients with progressive onset of chronic GVHD early after BMT received thalidomide concurrent with standard immunosuppressive therapy at the time of formal diagnosis of chronic GVHD. This accounts for the zero value at the lower limit of the range quoted above for the median duration of immunosuppressive therapy prior to thalidomide. These two patients had already received extensive steroid-based therapy for acute GVHD. The distribution of responses according to organ involved by chronic GVHD is shown in Figure 1 . All organs except lung showed improvement in at least some patients. Improvement was most commonly seen in cutaneous chronic GVHD. In five patients, joint dysfunction related either to arthritis or contractures was significantly alleviated. Responses were maintained to the date of last contact in all cases. The median duration of response, from time of starting thalidomide, was 18 months (range 3-42 months). The median duration of thalidomide therapy in the responding patients was 12 months (2-42 months), with at least eight of 14 patients achieving the target dose of thalidomide. There were no deaths among the responding patients. A relapse of primary disease (acute myelogenous leukemia) subsequently occurred in one responder.
Twenty-three patients (62%) showed no response. Of the non-responders, 21 died (at median 2 months, range 0.6-55 months) and two survive 6 and 34 months after starting thalidomide, one with bronchiolitis obliterans, and the other with progressive scleroderma. The median duration of thalidomide therapy in non-responding patients was only 1 month (range 0-55 months) though five patients achieved the target dose of thalidomide. Of note, the median duration of prior immunosuppressive therapy was 20 months (range 1-105 months) in responders compared to only 4 months (range 0-34 months) in non-responders. 
Survival analysis and mortality
The Kaplan-Meier estimate of survival from initiation of thalidomide therapy for this group of 37 patients with refractory chronic GVHD was 41% (24%-59%, 95% C.I.) at 2 years ( Figure 2 ). Survival at 2 years from initiation of thalidomide for recipients of related donor marrow was 58% (34-82%, 95% C.I.), compared to 24% (1-48%, 95% C.I.) for recipients of unrelated donor marrow (P = 0.17). There was a trend toward improved 2-year survival for children (51%, C.I. 27-76%) compared to adults (27%, C.I. 4-51%, P = 0.07) (Figure 3) . In a multivariate analysis, a shorter duration of chronic GVHD prior to initiation of thalidomide therapy was associated with shorter survival (RR 0.98: 95% C.I.; 0.97-0.99, P = 0.04). After adjustment for duration of chronic GVHD, neither age Ͼ18 (RR 1.9: 0.8-4.8, P = 0.16) nor unrelated donor grafts (RR 1.9: 0.7-4.8, P = 0.20) were independently significant adverse risk factors.
Twenty-one patients died after commencing thalidomide therapy (crude mortality 57%). There were no deaths due to relapse of primary disease. Chronic GVHD, with associated infection, was a major contributor to mortality in all patients who died. Fungal infection was identified in seven patients, either candida or aspergillus species. Viral infection with disseminated herpes zoster was a primary cause of death in one patient. Fatal intestinal perforation occurred in two patients, one of whom had a cecal perforation requiring ileostomy 2 days after starting thalidomide, in the setting of high-dose steroids. Non-infectious interstitial pneumonitis occurred in five patients. Bronchiolitis obliterans accounted for three deaths. One patient died from toxic epidermal necrolysis.
Toxicity
Constipation and somnolence were common adverse effects of thalidomide, occurring in over 80% of patients. However, these effects were usually well tolerated and thalidomide was only rarely discontinued because of these toxicities (constipation in one, somnolence in two).
Other adverse effects included a mild peripheral neuropathy in one patient, resulting in discontinuation of thalidomide. An apparent exacerbation of skin rash was noted in four patients shortly (less than 10 days) after starting thalidomide. In one case, there was a flare of pre-existing skin erythema which resolved while continuing thalidomide. A second patient developed significant skin erythema leading to discontinuation of thalidomide. Two patients developed severe whole body erythema. One patient recovered after discontinuation of thalidomide, the other died with fulminant biopsy-proven toxic epidermal necrolysis.
Discussion
We have shown that thalidomide can induce useful responses in chronic GVHD refractory to standard immunosuppressive therapy. The Kaplan-Meier 2-year survival of 41% in our group may be similar with previous experience in refractory chronic GVHD. 1, 9, 14 Parker et al reported a crude survival of 53% in a series of 80 patients receiving thalidomide as salvage therapy for chronic GVHD. 10 Although Vogelsang et al 9 reported a higher (actuarial) survival of 76% in refractory patients, differences in patient profile and extent of prior immunosuppression may account for this difference in part. The number of patients with progressive onset of chronic GVHD, a known adverse prognostic factor, 2 is comparable between our series and that of Vogelsang. However, our study included 20 patients receiving grafts from unrelated donors, eight of whom were only partially HLA-matched. Chronic GVHD may be particularly aggressive in this group. Furthermore, in the analysis of non-responders, the duration of prior immunosuppressive therapy appeared shorter (median 4 months) than in responders (median 20 months), and the majority of non-responders died within a short time (median 2 months) of starting thalidomide. The primary cause of death in almost every case was chronic GVHD, often with associated infection or organ failure. Early failure of first-line therapy for chronic GVHD may also be associated with poor responses to thalidomide. It is likely that these patients may have had an intrinsically more resistant form of chronic GVHD and may have commenced thalidomide too late in the course of their disease to observe an adequate response.
Overall, our experience with thalidomide is somewhat less encouraging than that of Vogelsang et al 9 though differences in the patient population and measures of response may, in part, explain the differences. We observed only one complete response. Furthermore, most (77%) of our partial responders were children, who may have less aggressive chronic GVHD than adults. 1, 4 Our definition of response included patients who demonstrated significant and durable clinical improvement in only one affected organ, with stable but not improved disease in other affected organs. This represents a clinically important outcome, but constitutes a less stringent definition of partial response than that used previously by Vogelsang, 9 which required greater than 50% reduction of measurable disease in all involved organs.
It may be argued that some of the observed responses in our patients could be attributed to other immunosuppressive agents given concomitantly with thalidomide. Against this, however, is the fact that the median duration of immunosuppressive therapy prior to starting thalidomide was 11 months, an interval sufficiently long to allow any potential benefit of such therapy to become apparent. Indeed, it is striking that the addition of thalidomide was associated with clinical benefit in such heavily pre-treated and previously unresponsive patients. Six of the 14 clinical responses occurred in patients receiving unrelated donor BMT, suggesting that thalidomide may be effective in this setting as well. Eight of the 14 responders had a progressive onset of chronic GVHD. It is becoming clear that such patients represent a significant therapeutic challenge. Early intervention with thalidomide may be beneficial for this group.
Thalidomide was well tolerated in most patients. Although sedation and constipation occurred in almost all patients, this rarely necessitated discontinuation of thalidomide therapy. The development of intestinal perforation in two patients who subsequently died cannot be related to thalidomide, although the possible contribution of thalidomide-induced autonomic dysfunction cannot be excluded. We observed significant peripheral neuropathy in only one patient, although transient paresthesias were more common. The potential exacerbation of underlying skin disease seen in four patients is of greater concern. In one patient, there was a clear temporal relationship between starting thalidomide and the development of fulminant toxic epidermal necrolysis. While this may have reflected coincidental progression of skin GVHD, it is also possible that thalidomide may have adverse dermatologic effects in the setting of immune dysfunction associated with chronic GVHD cannot be excluded. Erythematous reactions have been described previously in patients receiving thalidomide for lepromatous leprosy. 16 A severe skin rash was recognized recently in a patient treated for glioblastoma. 17 Recently, Parker et al 10 observed similar skin reactions in their series of patients receiving thalidomide for refractory chronic GVHD. Clearly, one should be alert for possible skin reactions during the initiation of thalidomide therapy for chronic GVHD.
We conclude that thalidomide may be a useful therapy for refractory chronic GVHD, including that occurring after unrelated donor BMT. The majority of responders were in the pediatric group. This effectiveness of thalidomide in children with chronic GVHD has also been noted by others. 11, 18, 19 Earlier introduction of thalidomide may be important, particularly in adults with aggressive disease. The ultimate role of thalidomide in therapy of chronic GVHD remains to be defined. In this regard, we are currently conducting a prospective randomized study of standard immunosuppressive therapy with or without thalidomide at the time of diagnosis of chronic GVHD in patients receiving either related or unrelated BMT.
